Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2025)
Historic Gross Profit for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to $64.7 million.
- Rigel Pharmaceuticals' Gross Profit rose 3686.05% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 8648.62%. This contributed to the annual value of $160.6 million for FY2024, which is 4633.15% up from last year.
- As of Q3 2025, Rigel Pharmaceuticals' Gross Profit stood at $64.7 million, which was up 3686.05% from $97.2 million recorded in Q2 2025.
- Over the past 5 years, Rigel Pharmaceuticals' Gross Profit peaked at $97.2 million during Q2 2025, and registered a low of $16.6 million during Q1 2022.
- For the 5-year period, Rigel Pharmaceuticals' Gross Profit averaged around $39.4 million, with its median value being $28.8 million (2022).
- Its Gross Profit has fluctuated over the past 5 years, first tumbled by 7941.31% in 2022, then surged by 18554.09% in 2025.
- Quarter analysis of 5 years shows Rigel Pharmaceuticals' Gross Profit stood at $19.9 million in 2021, then surged by 155.68% to $50.9 million in 2022, then crashed by 37.17% to $32.0 million in 2023, then soared by 61.89% to $51.8 million in 2024, then increased by 24.9% to $64.7 million in 2025.
- Its last three reported values are $64.7 million in Q3 2025, $97.2 million for Q2 2025, and $48.9 million during Q1 2025.